牡丹颗粒联合甲钴胺治疗2型糖尿病周围神经病变:双盲随机安慰剂对照多中心试验方案
本研究为一项14中心、双盲、随机、安慰剂对照、平行臂试验,计划纳入402例30-70岁2型糖尿病周围神经病变患者,按1:1随机分为牡丹颗粒联合甲钴胺组与安慰剂联合甲钴胺组,治疗24周,主要结局为密歇根糖尿病神经病变评分(MDNS),旨在评估牡丹颗粒联合甲钴胺的安全性与有效性。
要点
- 牡丹颗粒联合甲钴胺可能改善2型糖尿病周围神经病变症状,但需本试验验证。
- 主要结局为MDNS,在基线、治疗12周和24周时评估。
- 试验采用双盲、随机、安慰剂对照、多中心设计,计划纳入402例患者。
核心结论
- 本研究旨在评估牡丹颗粒联合甲钴胺治疗2型糖尿病周围神经病变的安全性与有效性,结果尚待报告。
研究设计与样本
- 本研究为14中心、双盲、随机、安慰剂对照、平行臂试验,计划纳入402例30-70岁2型糖尿病周围神经病变患者。
- 受试者按1:1随机分为干预组(n=201;牡丹颗粒+甲钴胺)和对照组(n=201;安慰剂+甲钴胺)。
- 治疗周期为24周,周期之间无治疗中断。
关键数值与推荐
- 主要结局为密歇根糖尿病神经病变评分(MDNS),在基线、干预期间12周和干预24周后评估。
- 不良事件与安全性评估也将被记录。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Diabetic peripheral neuropathy (DPN) characterized by nerve damage is a common and disabling chronic microvascular complication in patients with type 2 diabetic mellitus (T2DM), affecting at least half of patients diagnosed with T2DM. Unfortunately, the current treatment for DPN is not ideal. Traditional Chinese medicine (TCM), with a unique theoretical system, has made outstanding contributions in the treatment of T2DM and related complications. Mudan granule, a Chinese patent medicine, has been previously validated that could ameliorate the symptoms, promote nerve tissue repair, increase nerve conduction velocity (NCV) in patients with DPN. However, the previous studies are of variable quality, which limits the clinical application of Mudan granule. Therefore, we designed a double-blind, randomized, placebo-controlled, parallel-arm, multi-center trial to estimate the safety and efficacy of Mudan granule in conjunction with methylcobalamin in individuals suffering from type 2 diabetic peripheral neuropathy. Methods: This work is conducted as a 14-center, double-blind, randomized, placebo-controlled, parallel-arm trial. In all, 402 subjects (aged 30-70 years) will be recruited and randomized in a 1:1 ratio to an intervention group (n = 201; Mudan granule + methylcobalamin) and a control group (n = 201; placebo + methylcobalamin). Treatment is administered in 24 weeks cycles without any treatment interruption between cycles. Michigan Diabetic Neuropathy Score (MDNS) as the primary outcome will be evaluated at baseline, 12 weeks during the intervention period, and after 24 weeks of the intervention. Adverse events and safety assessments will be also documented. The analysis of all data will be carried out based on a predefined statistical analysis plan. Discussion: The outcomes from this study will offer important evidence regarding the safety and efficacy that Mudan granule can be used as an alternative and complementary therapeutic intervention in patients with type 2 diabetic peripheral neuropathy. Clinical trial registration: Registered at https://clinicaltrials.gov/. Trial registration number: NCT04711980. Registered January 2021.
引用
- Zhang Y, Jin D, Duan Y, et al. Efficacy of Mudan Granule (Combined With Methylcobalamin) on Type 2 Diabetic Peripheral Neuropathy: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm, Multi-Center Trial. Front Pharmacol. 2021. PMID: 34093204. doi:10.3389/fphar.2021.676503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。